Cancer 125
CA 125
Description
"Cancer Antigen 125" (CA-125) test measures the level of CA-125 protein in your blood, often used to monitor ovarian cancer risk or treatment response. Elevated levels may point to cancer, but can also reflect non-cancerous conditions like endometriosis or pelvic inflammation. Doctors typically order this test when symptoms like bloating, pelvic pain, or menstrual changes appear. Results help guide further evaluation or treatment planning. Ongoing CA-125 testing supports early detection and long-term care for those at higher risk.
Category
Proteins
Procedure
Non-Invasive
Sample Type
Blood – Serum
Units
Units Per Milliliter
Procedure Category
Blood Draw
Test Group
Chronic Illness Group
Test Group Description
Chronic Illness Group: This group encompasses a range of tests specifically tailored to assess markers associated with chronic health conditions, providing comprehensive insights into the management and monitoring of chronic illnesses.
Optimal Range
For All Individuals:
Conventional Unit: < 20.00 U/mL
SI Unit: Not Frequently Used
Normal Range
For All Individuals:
Conventional Unit: 0.00–35.00 U/mL
SI Unit: Not Frequently Used
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Bacterial infections
Colorectal cancer
Diverticulitis (inflammation or infection of pouches that can form in the colon)
Fibroids (non-cancerous growths in the uterus)
Inflammatory Bowel Disease (chronic inflammation of the digestive tract)
Liver disease
Ova...
Key Reasons For Testing
Monitoring Ovarian Cancer Treatment: Tracks how effective treatments are and whether the disease is being managed.
Assessment of Recurrence: Detects potential ovarian cancer recurrence by identifying rising CA-125 levels.
Evaluation of Treatment Response: Monitors chemotherapy or other treatments to guide adjustments in care.
Screening High-Risk Individuals: Supports early detection in women with family history or BRCA gene mutations.
Prognostic Indicator: Provides insights into cancer progression and patient outlook to guide care plans.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309(15):883-887.
[2] Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40-46.
[3] Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1-12.
[4] Montagnana M, Danese E, Ruzzenente O, et al. The role of CA 125 in clinical practice: utility in ovarian cancer and other conditions. Clin Chim Acta. 2009;408(1-2):1-7.
[5] Malkasian GD Jr, Knapp RC, Lavin PT, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Am J Obstet Gynecol. 1988;159(2):341-346.
[6] Zurawski VR Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer. 1988;42(5):677-680.
[7] Sölétormos G, Duffy MJ, Hassan SO, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43-51.
[8] Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76(10 Suppl):2092-2096.
[9] Yurkovetsky Z, Skates S, Lomakin A, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28(13):2159-2166.
[10] Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82(9):1535-1538.
[11] Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol.2005;193(5):1630-1639.
[12] Urban N, Thorpe JD. Marker-based ovarian cancer early detection in the general population: current and future perspectives. J Natl Compr Canc Netw. 2010;8(6):715-722.